Medical Marketing Moments

It's hard to believe that when this publication appeared 40 years ago, Tylenol was a relatively new product and the Medicare program was fresh out of the box. Of course, a lot has happened since then (not least to Tylenol and Medicare). Technology and the Internet have changed every facet of medical marketing, while regulatory shifts have opened the doors to DTC, and raised firewalls between education and promotion. MM&M has been there throughout, and we look forward to reporting on 40 more prosperous years for the industry.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.